Table 2.
Registry name | Retention period | Drug survival rate (%)
|
|||
---|---|---|---|---|---|
TCZ | IFX | ETA | ADA | ||
CORRONA45 | 24 months | 63 | 53 | 53 | |
LOHREN46 | 2.5 years | 56 | 72 | 57 | |
SCQM-RA47 | 2.5 years | 51 | 58 | 61 | |
GISEA48 | 2.5 years | 52 | 65 | 52 | |
DANBIO49,50 | 96 weeks | 54 | |||
48 months | 41 | 56 | 52 | ||
BiRD51 | 2.5 years | 79 | 47 | 78 | 55 |
Abbreviations: ADA, adalimumab; BiRD, Biologics for Rheumatic Diseases; CORRONA, Consortium of Rheumatology Researchers of North America; DANBIO, Danish Nationwide Rheumatological Database; ETA, etanercept; GISEA, Gruppo Italiano di Studio sulle Early Arthritides; IFX, infliximab; LOHREN, Lombardy Rheumatology Network; SCQM-RA, Swiss Clinical Quality Management for Rheumatoid Arthritis; TCZ, tocilizumab; TNF, tumor necrosis factor.